DIS vs. LLY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DIS and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DIS | LLY |
|---|---|---|
| Company Name | The Walt Disney Company | Eli Lilly and Company |
| Country | United States | United States |
| GICS Sector | Communication Services | Health Care |
| GICS Industry | Entertainment | Pharmaceuticals |
| Market Capitalization | 209.71 billion USD | 592.10 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 1962 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DIS and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DIS | LLY |
|---|---|---|
| 5-Day Price Return | 3.33% | 3.06% |
| 13-Week Price Return | 5.57% | -12.58% |
| 26-Week Price Return | 4.06% | -24.11% |
| 52-Week Price Return | 35.71% | -25.32% |
| Month-to-Date Return | -2.07% | -10.75% |
| Year-to-Date Return | 4.75% | -14.44% |
| 10-Day Avg. Volume | 11.20M | 8.71M |
| 3-Month Avg. Volume | 10.42M | 4.45M |
| 3-Month Volatility | 20.10% | 41.63% |
| Beta | 1.57 | 0.45 |
Profitability
Return on Equity (TTM)
DIS
11.10%
Entertainment Industry
- Max
- 42.50%
- Q3
- 22.75%
- Median
- 12.88%
- Q1
- 7.15%
- Min
- -6.84%
DIS’s Return on Equity of 11.10% is on par with the norm for the Entertainment industry, indicating its profitability relative to shareholder equity is typical for the sector.
LLY
88.36%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
DIS
12.22%
Entertainment Industry
- Max
- 45.25%
- Q3
- 23.93%
- Median
- 14.60%
- Q1
- 4.89%
- Min
- -22.94%
DIS’s Net Profit Margin of 12.22% is aligned with the median group of its peers in the Entertainment industry. This indicates its ability to convert revenue into profit is typical for the sector.
LLY
25.91%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
DIS
12.69%
Entertainment Industry
- Max
- 46.83%
- Q3
- 28.87%
- Median
- 15.26%
- Q1
- 8.95%
- Min
- -5.53%
DIS’s Operating Profit Margin of 12.69% is around the midpoint for the Entertainment industry, indicating that its efficiency in managing core business operations is typical for the sector.
LLY
32.37%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | DIS | LLY |
|---|---|---|
| Return on Equity (TTM) | 11.10% | 88.36% |
| Return on Assets (TTM) | 5.88% | 16.02% |
| Net Profit Margin (TTM) | 12.22% | 25.91% |
| Operating Profit Margin (TTM) | 12.69% | 32.37% |
| Gross Profit Margin (TTM) | 37.61% | 82.64% |
Financial Strength
Current Ratio (MRQ)
DIS
0.72
Entertainment Industry
- Max
- 6.80
- Q3
- 3.77
- Median
- 1.87
- Q1
- 0.86
- Min
- 0.39
DIS’s Current Ratio of 0.72 falls into the lower quartile for the Entertainment industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
LLY
1.28
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
DIS
0.39
Entertainment Industry
- Max
- 1.65
- Q3
- 0.71
- Median
- 0.14
- Q1
- 0.04
- Min
- 0.00
DIS’s Debt-to-Equity Ratio of 0.39 is typical for the Entertainment industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
LLY
2.18
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
DIS
7.95
Entertainment Industry
- Max
- 62.11
- Q3
- 31.19
- Median
- 7.50
- Q1
- 2.02
- Min
- -6.33
DIS’s Interest Coverage Ratio of 7.95 is positioned comfortably within the norm for the Entertainment industry, indicating a standard and healthy capacity to cover its interest payments.
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | DIS | LLY |
|---|---|---|
| Current Ratio (MRQ) | 0.72 | 1.28 |
| Quick Ratio (MRQ) | 0.66 | 0.53 |
| Debt-to-Equity Ratio (MRQ) | 0.39 | 2.18 |
| Interest Coverage Ratio (TTM) | 7.95 | 20.36 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DIS
0.83%
Entertainment Industry
- Max
- 2.54%
- Q3
- 1.29%
- Median
- 0.61%
- Q1
- 0.00%
- Min
- 0.00%
DIS’s Dividend Yield of 0.83% is consistent with its peers in the Entertainment industry, providing a dividend return that is standard for its sector.
LLY
0.82%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
LLY’s Dividend Yield of 0.82% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
DIS
46.10%
Entertainment Industry
- Max
- 82.30%
- Q3
- 45.76%
- Median
- 29.16%
- Q1
- 0.00%
- Min
- 0.00%
DIS’s Dividend Payout Ratio of 46.10% is in the upper quartile for the Entertainment industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
LLY
36.46%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | DIS | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.83% | 0.82% |
| Dividend Payout Ratio (TTM) | 46.10% | 36.46% |
Valuation
Price-to-Earnings Ratio (TTM)
DIS
18.03
Entertainment Industry
- Max
- 53.51
- Q3
- 45.31
- Median
- 33.16
- Q1
- 18.21
- Min
- 3.89
In the lower quartile for the Entertainment industry, DIS’s P/E Ratio of 18.03 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
LLY
44.55
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 44.55, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
DIS
2.20
Entertainment Industry
- Max
- 12.81
- Q3
- 7.20
- Median
- 4.68
- Q1
- 3.32
- Min
- 0.79
In the lower quartile for the Entertainment industry, DIS’s P/S Ratio of 2.20 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
LLY
11.54
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 11.54, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
DIS
2.04
Entertainment Industry
- Max
- 17.11
- Q3
- 8.38
- Median
- 5.24
- Q1
- 2.18
- Min
- 0.67
DIS’s P/B Ratio of 2.04 is in the lower quartile for the Entertainment industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
LLY
40.43
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | DIS | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 18.03 | 44.55 |
| Price-to-Sales Ratio (TTM) | 2.20 | 11.54 |
| Price-to-Book Ratio (MRQ) | 2.04 | 40.43 |
| Price-to-Free Cash Flow Ratio (TTM) | 18.03 | 305.94 |